Alterity Therapeutics (NASDAQ:ATHE) Director Peter Ashley Marks Buys 47,620 Shares of Stock

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Director Peter Ashley Marks purchased 47,620 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average cost of $0.50 per share, for a total transaction of $23,810.00. Following the purchase, the director owned 191,340 shares in the company, valued at $95,670. This represents a 33.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Alterity Therapeutics Stock Performance

Alterity Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, hitting $4.51. 16,172 shares of the company were exchanged, compared to its average volume of 17,598. The business has a fifty day moving average of $4.78 and a 200 day moving average of $4.31. Alterity Therapeutics Limited – Sponsored ADR has a 1-year low of $2.66 and a 1-year high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE) last issued its earnings results on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. As a group, analysts anticipate that Alterity Therapeutics Limited – Sponsored ADR will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC bought a new position in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ATHE. UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. Craig Hallum set a $2.00 price objective on shares of Alterity Therapeutics in a report on Tuesday, August 11th. JonesTrading assumed coverage on shares of Alterity Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $16.00 target price for the company. LADENBURG THALM/SH SH initiated coverage on Alterity Therapeutics in a report on Tuesday, June 16th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Zacks Research upgraded Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.